蓝芩口服液治疗慢性咽炎随机对照试验系统评价和Meta分析.docVIP

蓝芩口服液治疗慢性咽炎随机对照试验系统评价和Meta分析 　　[摘要] 系统评价蓝芩口服液治疗慢性咽炎的疗效和安全性。计算机检索PubMed，Embase，Cochrane Library，CBM，CNKI，VIP，万方科技数据库，收集蓝芩口服液治疗慢性咽炎的随机对照研究，检索时限均为从建库至2017年3月，由2名研究者按照纳入和排除标准独立进行文献筛选、资料提取，用Cochrane偏倚评估手册进行质量评价并交叉核对。采用RveMan.5.3软件进行数据分析。共纳入13个随机对照试验，共计1 642例慢性咽炎患者。Meta分析结果显示： ①有效率：蓝芩口服液治疗组优于对照组（常规治疗或其他药物治疗）；②IL-2：蓝芩口服液治疗组优于对照组（MD及95% CI，2.20[1.91，2.48]，P0.000 01）；③TNF-α：蓝芩口服液治疗组优于对照组（MD及95%CI，0.75[0.60，0.90]，P0.000 01）；④不良反应：无安全性信息报告。基于现有临床证据，蓝芩口服液治疗慢性咽炎的有效率优于常规治疗或其他药物治疗。但由于纳入研究的方法学质量普遍较低，需要严格方法学设计和质量控制的临床研究提供高质量的证据。 　　[关键词] 蓝芩口服液；慢性咽炎；随机对照试验；系统评价；Meta分析 　　Lanqin oral liquid for the treatment of chronic pharyngitis： 　　systematic review and Meta-analysis of randomized clinical trials 　　LI Na1，YANG Feng-wen1，LU Zhong-ying1，ZHANG Dong2，LIU Chun-xiang2，ZHENG Wen-ke2 　　（1. Tianjin University of Traditional Chinese Medicine，Tianjin 300193，China； 　　2. Center for Evidence-Based Medicine，Tianjin University of Traditional Chinese Medicine，Tianjin 300193，China） 　　[Abstract] To systematically assess the effectiveness and safety of lanqin oral liquid for the treatment of chronic pharyngitis. Databases including PubMed，Embase，The Cochrane Library，SinoMed，CNKI，VIP and Wanfang Data were electronically searched in March 2017 for randomized controlled trials（RCTs） on Lanqin oral liquid for the treatment of chronic pharyngitis. Two authors independently screened literature，extracted data，and assessed the risk of bias of included studies. Then，meta-analysis was performed by RevMan 5.3 software. Thirteen RCTs were included with a total of 1 642 patients. The results of meta-analysis showed that the efficiency of lanqin oral liquid were significantly higher than those of conventional therapy or other treatments；Besides，lanqin oral liquid could significantly increase the amount of IL-2 further more，lanqin oral liquid could significantly reduce the amount of TNF-α. Safety of lanqin oral liquid was not concerned by any RCT. Current evidence indicates that the efficiency of lanqin oral l